A PYMNTS Company

US: Pet healthcare firm announces nearly $20M takeover

By  |  October 14, 2013

Aratana Therapeutics, which specializes in medical innovation technologies for pets, announced plans to acquire Vet Therapeutics in a $19.75 million deal the company expects will expand operations into the biologics platform.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a press release, the buyout will help Aratana enter the commercial pet therapeutics market.

    Vet Therapeutics is best known for its product to treat canine T-cell lymphoma, which is currently under review by the US Department of Agriculture.

    Full Content: Benzinga

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.